Tumor News and Research

RSS

ASU-led researchers add new worldwide resource to explore genes' deep and hidden messages

After a decade-long $3 billion international effort, scientists heralded the 2001 completion of the human genome as a moon landing achievement for biology and the key to finally solving intractable diseases like cancer.

12 Dec 2015

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

11 Dec 2015

Researchers find new method to create uniform standards in search for cancer-relevant mutations

Oncologists are increasingly using information obtained from investigations of the tumor genome in order to find individualized therapies for patients. They specifically search the hereditary information of cancer cells for mutations that drive malignant growth. By now, targeted drugs against many of these cancer-typical cellular alterations have become available.

11 Dec 2015

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

11 Dec 2015

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.

11 Dec 2015

TBK1 protein plays vital role in the process of cell division

Moffitt Cancer Center researchers have found that a protein called TBK1 plays an important role in the process of cell division, especially at a stage called mitosis.

11 Dec 2015

Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center.

11 Dec 2015

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

10 Dec 2015

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

The first Toulouse Onco Week (TOW) is due to take place from 3 to 6 February 2016 at the Pierre Baudis Congess Center, Toulouse, France. This unique event will be focused on the international fight against cancer by bringing together stakeholders from around the world and presenting the latest global innovations in oncology.

10 Dec 2015

Scientists discover that blocking RANKL protein stops osteosarcoma

Scientists at Princess Margaret Cancer Centre have discovered that blocking the master regulator of bone renewal stops osteosarcoma - the most common primary bone cancer in children and teens, and the malignant disease that was fatal for Canadian icon Terry Fox.

10 Dec 2015

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Pulmonary hypertension is an umbrella term used for many conditions that all result in elevation of the pulmonary arterial pressure. Of interest, many of these completely different clinical and pathophysiological entities result in a final common pathway of vasoconstriction, micro thrombosis and vascular remodelling.

10 Dec 2015

TET proteins needed to maintain genome instability, say researchers

Members of the TET (short for ten-eleven translocation) family have been known to function as tumor suppressors for many years, but how they keep a lid on the uncontrolled cell proliferation of cancer cells had remained uncertain. Now, researchers at the La Jolla Institute for Allergy and Immunology demonstrate that TET proteins collectively constitute a major class of tumor suppressors and are required to maintain genome instability.

9 Dec 2015

New three-drug delivery system shows promise for treatment of metastatic melanoma

Researchers have developed a new three-drug delivery system for cancer treatment, especially metastatic melanoma, the deadliest form of skin cancer - and shown that the system may have particular value with cancers like this that often spread through the lymphatic system.

9 Dec 2015

Dietary sugar may help to treat melanoma

New research from scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) suggests that a rare sugar found in seaweed, mushrooms, seeds and other foods may be able to help treat skin cancer.

9 Dec 2015

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

9 Dec 2015

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its liquid biopsy testing menu to include two new tests, a NeoLAB Solid Tumor Monitor and a NeoLAB BTK Inhibitor Acquired Resistance test.

8 Dec 2015

Tumor News and Research

ASU-led researchers add new worldwide resource to explore genes' deep and hidden messages

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

Researchers find new method to create uniform standards in search for cancer-relevant mutations

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Study reveals why anti-hormone therapy tamoxifen works better in some women than others

TBK1 protein plays vital role in the process of cell division

Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Lilly, Merck announce another immuno-oncology collaboration

Renowned experts, Nobel laureates to convene at Toulouse Onco Week to discuss latest advances in oncology

Scientists discover that blocking RANKL protein stops osteosarcoma

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

TET proteins needed to maintain genome instability, say researchers

New three-drug delivery system shows promise for treatment of metastatic melanoma

Dietary sugar may help to treat melanoma

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

OncoSec reports net loss of $7.0 million for first quarter of fiscal 2016

Scientists reveal why loss of CD73 enzyme in human cancer promotes tumor progression

New Loyola Center for Cancer Care & Research opens at Palos Community Hospital

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News